Cyclooxygenase-2 Expression Correlates With Membrane-Type-1 Matrix Metalloproteinase Expression in Colorectal Cancer Tissue

Guo, Hongfei; Tatsuguchi, Atsushi; Shinji, Seiichi; Fujimori, Shunji; Tanaka, Shu; Gudis, Katya; Sugisaki, Yuichi; Furukawa, Kiyonori; Tajiri, Takashi; Fukuda, Yuh; Kishida, Teruyuki; Sakamoto, Choitsu

doi:10.1007/s10350-006-0588-0

Cited by 4 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COX-2 expression alone did not correlate with patient survival, consistent with previous studies [24,27]. In contrast, survival rates were significantly lower for stage I-III patients with mPGES-1-positive tumors than for patients with mPGES-1-negative tumors.…”

Section: Discussionsupporting

confidence: 87%

“…3f) in all cases examined and thus determined constitutive. COX-2 immunoreactivity was found in cancer cells in 91% of cases (141/155), consistent with previous reports [24,25].…”

Section: Cox-2 Mpges-1 Mpges-2 and Cpges Protein Levels In Colorecsupporting

confidence: 92%

“…Any disagreement was resolved using a multi-headed microscope. Cases showing COX-2 immunoreactivity in over 10% of cancer cells were considered positive, as previously described [24,25]. Cases showing mPGES-1 immunoreactivity in over 5% of cancer cells were considered positive, as previously described [20].…”

Section: Evaluation Of Immunohistochemical Stainingmentioning

confidence: 99%

See 2 more Smart Citations

Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients

et al. 2009

Self Cite

View full text Add to dashboard Cite

The aim of this study is to investigate the expression of three prostaglandin E synthase (PGES) isomers in colorectal cancer (CRC) tissue and to evaluate their relationship to clinicopathological factors and patient prognosis. Microsomal PGES (mPGES)-1, mPGES-2, cytosolic PGES (cPGES) and cyclooxygenase (COX)-2 protein expression were analyzed by real-time polymerase chain reaction and Western blot. The localization of each PGES and COX-2 protein was examined by immunohistochemistry in 155 surgical resections and correlated to clinicopathological factors and patient prognosis. mPGES-1 mRNA and protein levels were significantly higher in CRC than in paired normal tissues. mPGES-1 immunoreactivity localized in cancer cells in 43% of cases. mPGES-2 immunoreactivity was significantly more pronounced in cancer cells than in adjacent normal epithelium in 36% of cases. cPGES immunoreactivity was homogeneous in cancer cells and thus determined constitutive. mPGES-1 and mPGES-2 correlated with significantly worse prognosis in stage I-III patients. These results indicate that mPGES-1 and mPGES-2 may each play a role in CRC progression.

show abstract

Section: Discussionsupporting

confidence: 87%

“…3f) in all cases examined and thus determined constitutive. COX-2 immunoreactivity was found in cancer cells in 91% of cases (141/155), consistent with previous reports [24,25].…”

Section: Cox-2 Mpges-1 Mpges-2 and Cpges Protein Levels In Colorecsupporting

confidence: 92%

See 1 more Smart Citation

Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our analysis also documented frequent COX-2 overexpression in colorectal carcinomas (86 percent of cases), in accordance with results previously reported. 4,14,[19][20][21][22] Furthermore, it highlighted the high expression rate of this enzyme in colorectal cancer by showing COX-2 staining in more than 70 percent of neoplastic cells in the majority of positive cases (62 percent).…”

Section: Discussionmentioning

confidence: 96%

“…[9][10][11][12][13] The role of COX-2 in colorectal carcinogenesis has been extensively studied, 4,14-18 and its overexpression has been documented in colorectal adenomas and adenocarcinomas. 15,16,[19][20][21][22] It has been demonstrated that it contributes to colorectal cancer development through effects partially dependent on the production of PGE 2 . 4 Such effects involve activation of carcinogens, induction of cell proliferation, inhibition of apoptosis, and induction of angiogenesis.…”

mentioning

confidence: 99%

5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage

Barresi¹,

Grosso²,

Vitarelli³

et al. 2007

Diseases of the Colon &Amp; Rectum

View full text Add to dashboard Cite

show abstract

Clinical use and pharmacological properties of selective COX-2 inhibitors

Shi

Klotz

2007

Eur J Clin Pharmacol

157

View full text Add to dashboard Cite

Selective COX-2 inhibitors (coxibs) are approved for the relief of acute pain and symptoms of chronic inflammatory conditions such as osteoarthritis (OA) and rheumatoid arthritis (RA). They have similar pharmacological properties but a slightly improved gastrointestinal (GI) safety profile if compared to traditional nonsteroidal anti-inflammatory drugs (tNSAIDs). However, long-term use of coxibs can be associated with an increased risk for cardiovascular (CV) adverse events (AEs). For this reason, two coxibs were withdrawn from the market. Currently celecoxib, etoricoxib, and lumiracoxib are used. These three coxibs differ in their chemical structure and selectivity for COX-2, which might explain some of their pharmacological features. Following oral administration, the less lipophilic celecoxib has a lower bioavailability (20-40%) than the other two coxibs (74-100%). All are eliminated by hepatic metabolism involving mainly CYP2C9 (celecoxib, lumiracoxib) and CYP3A4 (etoricoxib). Elimination half-life varies from 5 to 8 h (lumiracoxib), 11 to 16 h (celecoxib) and 19 to 32 h (etoricoxib). In patients with liver disease, plasma levels of celecoxib and etoricoxib are increased about two-fold. Clinical efficacies of the coxibs are comparable to tNSAIDs. There is an ongoing discussion about whether the slightly better GI tolerability (which is lost if acetylsalicylic acid is coadministered) of the coxibs is offset by their elevated risks for CV AEs (also seen with tNSAIDs other than naproxen), which apparently increase with dose and duration of exposure. In addition, the higher costs for coxibs (if compared to tNSAIDs, even when a "gastroprotective" proton pump inhibitor is coadministered) should be taken into consideration, if a coxib will be selected for certain patients with a high risk for GI complications. For such treatment, the lowest effective dose should be used for a limited time. Monitoring of kidney function and blood pressure appears advisable. It is hoped that further controlled studies can better define the therapeutic place of the coxibs.

show abstract

Cyclooxygenase-2 Expression Correlates With Membrane-Type-1 Matrix Metalloproteinase Expression in Colorectal Cancer Tissue

Cited by 4 publications

References 43 publications

Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients

Microsomal prostaglandin E synthase protein levels correlate with prognosis in colorectal cancer patients

5-Lipoxygenase is Coexpressed with Cox-2 in Sporadic Colorectal Cancer: A Correlation with Advanced Stage

Clinical use and pharmacological properties of selective COX-2 inhibitors

Contact Info

Product

Resources

About